Press Releases | Sophrosyne Pharmaceuticals

Our Focus Who We Are Pipeline Updates

Press Releases

All Press Releases Publications Corporate Info

Sophrosyne Pharmaceuticals Announces Dosing of First Subject in Phase I Study of Its Lead Asset for the Treatment of AUD

Apr 8, 2026|Press Releases

Sophrosyne Pharmaceuticals Invited to Present at the Oppenheimer Healthcare Life Sciences Conference

Feb 18, 2026|Press Releases

Sophrosyne Pharmaceuticals Announces Publication of Preclinical Findings for Its Lead Asset for Treatment of AUD

Jan 20, 2026|Press Releases

Sophrosyne Pharmaceuticals Announces Formation of Scientific Advisory Board Consisting of Preeminent Key Opinion Leaders

Nov 3, 2025|Press Releases

Sophrosyne Pharmaceuticals Receives FDA Clearance to Initiate Phase 1 Study with its Lead Product for the Treatment of Alcohol Use Disorder (AUD)

Sep 30, 2025|Press Releases

Sophrosyne Pharmaceuticals Appoints Herman Cukier as CEO

Aug 26, 2025|Press Releases